REPL Stock Analysis: Buy, Sell, or Hold?
REPL - Replimune Group, Inc.
$1.70
-3.06 (-64.29%)
▼
5d:
-80.09%
30d:
-77.57%
90d:
-78.83%
WAIT
LOW Confidence
Analysis Updated: Apr 13, 2026 12:00 AM ET
Earnings: May 28, 2026
Smart Money Accumulation
REPL is down 29.7% this week, but smart money is accumulating calls. Top strike: $10 2026-05-15 with 860 OI. Call ratio: 89% View Scanner →
Strength: 10.0/10
Get Alerted When REPL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: REPL is down 80.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: REPL is down 80.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: REPL is currently trading at $1.70, which is considered oversold relative to its 30-day fair value range of $5.75 to $8.43.
Technical Outlook: Technically, REPL is in a downtrend. Immediate support is located at $1.50, while resistance sits at $8.85. Short-term momentum is weak, with the stock down 64.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.86 (+656.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, REPL is in a downtrend. Immediate support is located at $1.50, while resistance sits at $8.85. Short-term momentum is weak, with the stock down 64.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.86 (+656.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$5.75 -
$8.43
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding REPL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-64.3%)
- BULLISH: Trading 656.3% below Wall St target ($12.86)
- WARNING: Recommendation downgraded due to -80.1% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$5.75 -
$8.43
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.50
Resistance Level
$8.85
Current Trend
Downtrend
Technical data as of
Apr 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.85
Wall Street Target
$12.86
(+656.3%)
Share & Embed Analysis
Last updated: April 13, 2026 6:30 PM ET
Data refreshes hourly during market hours. Next update: 7:30 PM
Data refreshes hourly during market hours. Next update: 7:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REPL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Sarchi
SELL
6500 shares
2026-04-02
Kapil Dhingra
SELL
3169 shares
2025-12-09
Sushil Patel
SELL
10000 shares
2025-12-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 60 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 61 BUY |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$212 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 52 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 57 HOLD |
Advanced REPL Option Strategies
Professional options setups generated by AI based on today's REPL price and gamma walls.
